Designing Phase 1 studies when the site is digital

Phase 1 is where risk is highest and certainty is lowest. Doses are conservative, but you're still asking people to be first. In that context, the clinical environment isn't just practical infrastructure: it's a safety net.

Which is why moving Phase 1 studies into digital or hybrid settings requires something more than moving the paperwork online. The systems that support early-phase research need to work fast, flag problems early, and keep investigators in control at every step. That's a very different brief from a standard EDC implementation. It's also, encouragingly, one the evidence now supports rather than just theorises about. A Pfizer-run feasibility study tested a hybrid decentralised design in a Phase 1 crossover trial with eight healthy participants, comparing self-collected pharmacokinetic microsamples against conventional venous samples and using wearable devices to capture ECG and vital signs remotely in real time. The self-collected PK data held up against the conventional method, and the wearables gave the study team a genuine, live safety picture without anyone in the room. The technology side of digital Phase 1 is no longer the open question. The system design around it is.

Here's what it actually takes to design a Phase 1 study when the site is digital.

Oversight that's measured in hours, not days

In a traditional clinic, an investigator spots a problem during a visit. In a remote setting, that same signal might sit unreviewed in a dashboard until someone logs in on Monday morning. That's not good enough. Digital Phase 1 infrastructure needs to surface individual participant data, not just aggregated summaries, with enough immediacy that the team can act: alerts triggered by specific values rather than only trends, symptom reports routed to named team members, and escalation paths embedded directly in the platform rather than written in an SOP nobody reads during an actual incident. Standard monitoring dashboards aren't built for this. Phase 1 requires something closer to real-time watchfulness, which is exactly what the wearable-based remote monitoring in the Pfizer study was designed to demonstrate was achievable.

Communication that doesn't wait for office hours

A participant experiences an unexpected symptom at 11pm. In a traditional inpatient Phase 1 setting, there's a nurse on the ward. In a remote setting, there's whatever the study team built. This is where many hybrid Phase 1 designs fall short. The asynchronous communication patterns that work fine in a nutritional study or a long-term observational design are too slow here. What's needed instead is direct in-app messaging between participants and staff, symptom-specific alert logic that routes by severity, and escalation steps that are clearly visible to both the participant and the team. If a participant doesn't know who to contact, or has to leave the app to make a phone call, the communication design has failed.

Dose escalation that's tracked, not assumed

Phase 1 protocols often involve staged cohorts and sequential dose increases. In a physical clinic, an investigator signs off before the next participant moves forward. In a digital environment, that checkpoint can quietly disappear. It shouldn't. The platform should track cohort progression against protocol criteria, lock subsequent tasks until sign-off criteria are met, and require documented investigator authorisation before escalation, not a checkbox, a verified record. The audit trail here isn't just administrative. It's the evidence that every step was approved by the right person, at the right time, based on the right information.

Consent and re-consent done properly

Phase 1 protocols change. Safety language gets updated. New dosing information emerges. Participants often need to re-consent mid-study, sometimes more than once. In a paper environment, that means coordinating site visits and chasing signatures. In a digital environment, it should mean new consent versions distributed immediately with timestamped confirmation, a clear record of which version each participant reviewed and when, and no ambiguity about whether the latest version was actually seen.

What hybrid actually means

Some Phase 1 studies will always need on-site elements: drug administration, blood draws, supervised observation windows. Digital doesn't replace these. It supports them, in much the same combination the Pfizer study used: an on-site or supervised dose, followed by remote, device-supported monitoring for the days after. The clinician documents dosing directly in the eCRF. The participant logs remote symptoms in the days following the visit. Video consultations replace follow-up phone calls. The digital layer wraps around the on-site activity, not the other way around.

The goal isn't to remove the site from Phase 1. It's to give the study team visibility and control even when the participant is at home. Safety works as the foundation, not a feature to be configured in sprint two.